ArticleJournal for immunotherapy of cancer2025

First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancer.

Nehal J Lakhani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.